Our findings shed new lights on the intricate war between cancer cells and the immune system, uncover a molecular mechanism of exhausted T cell persistence that involves the interactions between PD-1 and the Gal-9/TIM-3 cell death pathway, and demonstrate Gal-9 as a promising target for future generations of immune checkpoint therapy. The gene discussed is PDCD1; the disease is cancer.